Clinical trials: Adults With Overweight and Obesity
Diabetes Mellitus, Type 1, Overweight and Obesity
ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)
An initial pilot and feasibility study will be conducted using a Sequential, Multiple Assignment, Randomized Trial (SMART) design to identify acceptable and effective dietary strategies to optimize both glycemic control and…
- Trial name
- ACT1ON DP3 (NCT03651622)
- Testing
- Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of North Carolina, Chapel Hill
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity.
- Trial name
- NCT04707313
- Testing
- PF-06882961 (Cohorts 1 and 2), PF-06882961 (Cohort 3)
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 628 people
- Sponsor
- Pfizer
Obesity, Overweight or Obesity
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks.
- Trial name
- VESPER-1 (NCT06712836)
- Testing
- MET097
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Obesity
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose.
- Trial name
- NCT00563368
- Testing
- VI-0521, topiramate, phentermine
- Where
- 2 sites in United States
- Volunteers
- 756 people
- Sponsor
- VIVUS LLC
Obesity
Remote Delivery of Weight Management for Adults With IDD
The purpose of this study is to compare different weight loss programs in people with IDD to see which program works better.
- Trial name
- NCT03291509
- Testing
- Video Conference Meetings, In-person Meetings, Enhanced Stop Light Diet
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Kansas Medical Center
Chronic Disease, Hypertension
Rehabilitation in Primary Care: A Project to Maximize the Health Status of Adults With Chronic Illness
The purpose of the study is to determine whether occupational therapy and physiotherapy delivered in a primary care setting to adults with chronic illness is effective in improving health.
- Conditions
- Chronic Disease, Hypertension, Back Pain, Obesity
- Trial name
- NCT00229957
- Testing
- Occupational therapy, Physiotherapy, Self-management
- Where
- Canada
- Volunteers
- 303 people
- Sponsor
- Hamilton Health Sciences Corporation
Overweight and Obesity
Study of Produce Prescription Programs in Adults With Overweight or Obesity Experiencing Nutrition Insecurity
The goal of this study is to understand the best practices for implementing produce prescriptions among adults with overweight or obesity experiencing nutrition insecurity.
- Trial name
- NCT06751563
- Testing
- Behavioral Text Messages and Produce Box Delivery, Behavioral Text Message Program and Produce Voucher
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Johns Hopkins University
Overweight and Obesity
Inhibitory Control Adult Weight Management
The purpose of this pilot study is to explore the benefits of supplementing the WW (formerly Weight Watchers) online program with a cognitive training game (PolyRules!) among adults with overweight or obesity.
- Trial name
- NCT04747886
- Testing
- WW Only, WW + PolyRules!
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Aging, Diabetes Mellitus, Type 2
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management.
- Conditions
- Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
- Trial name
- NCT05786521
- Testing
- Semaglutide Injectable Product, Lifestyle Counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prader-Willi Syndrome
Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
The purpose of this study is to investigate over a 6 month period the effect of octreotide therapy on food intake, sense of hunger, body weight, body composition, efficiency of burning calories, biomarkers of weight regulation…
- Trial name
- NCT00399893
- Testing
- Octreotide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Duke University
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease, Type 2 Diabetes
- Trial name
- GLP1-SGLT2-CKM (NCT07465926)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor
- Volunteers
- 451,036 people
- Sponsor
- Chung Shan Medical University
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or…
- Trial name
- NCT06230523
- Testing
- Eloralintide
- Where
- 43 sites in United States
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Log2Lose: Incenting Weight Loss and Dietary Self-monitoring in Real-time to Improve Weight Management Among Adults With Obesity
This study involves an evaluation of whether providing small incentives weekly for dietary self-monitoring and/or weight loss improves short- and long-term weight loss. Participants can expect to be on study for 18 months.
- Trial name
- NCT04770909
- Testing
- Incentives for dietary self-monitoring and weight loss, Incentives for dietary self-monitoring, Incentives for weight loss
- Where
- 2 sites in United States
- Volunteers
- 706 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Diabetes Mellitus, Obesity
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control.
- Trial name
- NCT05579977
- Testing
- PF-07081532, Rybelsus
- Where
- 90 sites in United States, Bulgaria and 6 more
- Volunteers
- 902 people
- Sponsor
- Pfizer
Type 1 Diabetes, Obesity
ADJUnct Semaglutide Treatment in Type 1 Diabetes
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
- Trial name
- ADJUST-T1D (NCT05537233)
- Testing
- Semaglutide
- Where
- 4 sites in United States
- Volunteers
- 115 people
- Sponsor
- Viral N. Shah
Obesity, Type 2 Diabetes
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
- Trial name
- NCT00553787
- Testing
- VI-0521
- Where
- 6 sites in United States
- Volunteers
- 2,487 people
- Sponsor
- VIVUS LLC
Metabolic Syndrome, Metabolic Endotoxemia
Alleviation Of Metabolic Endotoxemia In Adults With Metabolic Syndrome With Milk Fat Globule Membrane
Metabolic syndrome (MetS) adults (n = 24; 18-65 y) will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial.
- Trial name
- NCT03860584
- Testing
- MFGM-enriched full-fat dairy milk, Soy phospholipid/lecithin milk
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University